This e-learning course focusses on effects of SGLT2 inhibitors on outcomes in CKD patients and (potential) mechanisms of SGLT2 inhibitors. Member registration (free) is needed to enroll in this course.
The SGLT2 inhibitor dapagliflozin reduced the primary endpoint and all secondary endpoints in the phase 3 DAPA-CKD trial, that enrolled CKD patients with and without T2DM.
T2DM patients who developed HF alone or in combination with stroke, CKD or PAD had the highest 5-year risk of death and the greatest decrease in lifespan when compared with development of other CV and renal diseases.
Recent CVOTs with GLP-1RAs included kidney outcomes as a secondary endpoint. Johannes Mann presents kidney results of these trials and raises questions from a nephrologist's perspective.
Prof. Wanner presents a case of a CKD patient who has developed diabetes. He discusses what the optimal treatment strategy for such a patient is and how new treatments have resulted in a paradigm shift in nephrology.
Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.
This post-hoc analysis demonstrated similar BP reductions after renal denervation (RDN) across high-risk subgroups and ASCVD risk scores. Reductions were sustained up to 3 years after RDN.
Maria Rosa Constanzo explains the function of SGLT2 in the early proximale tubule of the kidney in detail and discusses how blockade of SGLT2 may result in beneficial effects.
ERA-EDTA 2020 The initial eGFR dip after initiation of empagliflozin has raised some concerns. A post-hoc analysis was therefore performed to investigate the impact of an eGFR dip.
ERA-EDTA 2020 An analysis of pooled data from CVOT trials that evaluated semaglutide showed that semaglutide slowed down decline of eGFR compared to placebo.
Mark Cooper gives an overview of older glucose lowering therapies and more recent newer treatment options, with a focus on SGLT2 inhibitors, and their effect on kidney outcomes in CDK and DKD patients. With question
ERA-EDTA 2020 This genetic association study showed that homozygous rs10754555 NLRP3 variant carriers have a significantly higher risk of CV mortality, compared to non-carriers.